"Whether it's this year or next year, the odds of another economic downturn are high — and growing," Warren says.Politicsread more
A group of gold miners stocks "BAANG" are better plays than mega-cap FAANG names, according to John Roque, technical analyst at Wolfe Research.Marketsread more
Equifax will give consumers a range of options for monitoring their credit or making claims of fraud or data misuse, part of a $425 million restitution fund.Technologyread more
The agreement between the White House and congressional Democrats would raise the debt ceiling for two years and permanently end the sequester.Politicsread more
Microsoft and OpenAI announced a new partnership to build artificial general intelligence to tackle more complex tasks than current AI.Technologyread more
There's a reason the film industry doesn't measure the success of modern movies against those of the past — movie ticket inflation isn't an exact science.Entertainmentread more
A US judge presiding over multidistrict litigation alleging J&J's talc baby powder causes ovarian cancer starts hearing from experts Monday.Health and Scienceread more
Air-conditioner maker Lennox International pointed to colder weather as a key reason for cutting guidance and underperforming in the second quarter.Marketsread more
Following a record breaking opening weekend for Disney's "The Lion King," CNBC's Jim Cramer said the company's stock is an "annunity stream" for investors.Investingread more
The Iranian Intelligence Ministry held a briefing on Monday where they announced the alleged spies were Iranian citizens but trained by the CIA.World Newsread more
Two traders say Boeing's on the path to recovery.Trading Nationread more
The largest U.S. drugmaker is paying a hefty premium of 62% to get access to Array's approved treatments for skin cancer as well as its other experimental drugs.
Under new Chief Executive Officer Albert Bourla, Pfizer has been exploring ways to diversify its pipeline as its blockbuster pain drug Lyrica loses patent protection.
The company has also been pushing its "15 in 5" plan to launch 15 experimental treatments, each with at least $1 billion annual sales potential, over a five-year period and has been investing in cancer drugs and gene therapies.
In a conference call in April, Pfizer said it was considering "bolt-on" deals worth a few billion dollars to complement its pipeline.
Pfizer is paying $48 per Array share, which rose 60% to $47.38 in light premarket trading. Pfizer's shares were marginally higher.
The U.S. Food and Drug Administration last year approved Array's oral combination treatment for use in patients with melanoma - the deadliest form of skin cancer.
The company is also testing its triple combo therapy in colorectal cancer patients.
"(The acquisition) sets the stage to create a potentially industry-leading franchise for colorectal cancer alongside Pfizer's existing expertise in breast and prostate cancers," Bourla said.
Pfizer said it expects to complete the deal in the second half of 2019.
The transaction is expected to add to earnings beginning 2022, and will reduce adjusted earnings per share by between 4 and 5 cents this year and in 2020, Pfizer said.
Pfizer said it expects to finance the majority of the deal, which has an enterprise value of about $11.4 billion, with debt and the remaining with existing cash.